Closeup of a Petri Dish 1.jpg
Asana BioSciences to Present Phase 1 Clinical Safety and Efficacy Data of Oral, Once-Weekly, ASN007, a Novel ERK 1/2 Inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 

October 2019

 LAWRENCEVILLE, N.J, October 24, 2019 - Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present ASN007 data on clinical safety and efficacy in solid tumor patients at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference to be held in Boston, MA on October 26-30, 2019. The Scientific Committee selected the ASN007 late breaking abstract submission as one of the top ten abstracts for this year’s program and invited presentation as a short-talk. 

Closeup of a Petri Dish
Asana BioSciences Strengthens Leadership Team as ASN002 Phase 2b RADIANT Trial in Atopic Dermatitis Advances with a Second Positive DSMB Recommendation 

February 2019

 Lawrenceville, NJ, February 26, 2019 – Asana BioSciences, a clinical stage biopharmaceutical company focused on discovery and development of innovative medicines in immunology/inflammation and oncology, today announced the appointment of Shashank Mahashabde as Vice President of Chemistry, Manufacturing and Controls (CMC) and Pablo Jimenez, MD, FAPCR as Vice President and Therapeutic Area Head of Immunology. 

400px-Clear-Molecule.jpg
Asana BioSciences to Present Correlation Between Microbiome Changes and Clinical Efficacy With JAK/SYK Inhibitor ASN002 in the Late-Breaking News Session at the American Academy of Dermatology (AAD) Annual Congress

February 2019

Lawrenceville, NJ, February 18, 2019 – Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present ASN002 data demonstrating changes in skin microbiome and correlation with clinical efficacy in patients with moderate-to-severe atopic dermatitis. These data will be presented in a late-breaking news session at the AAD Annual Congress in Washington, D.C. to be held March 1-5, 2019. 

Asana BioSciences Announces Initiation of First-in-Human Clinical Study with ASN008, a Novel Topical Product for the Treatment of Pruritus Associated with Atopic Dermatitis

December 2018

Lawrenceville, NJ, December 20, 2018 - Asana BioSciences, a clinical stage biopharmaceutical company, announced today that it has been granted permission by the U.S. Food and Drug Administration (FDA) to start human clinical trials with ASN008, a topical gel for the treatment of pruritus (itch) associated with atopic dermatitis.

BioWorld Publishes Article on the FDA Fast Track Designation for ASN002, for Atopic Dermatitis

December 2018

BioWorld, December 11, 2018 - BioWorld has published an interview that was conducted with Dr. Sandeep Gupta, Founder, President and CEO of Asana BioSciences, to discuss the company portfolio and strategy, and the recent FDA Fast Track Designation for ASN002, an oral JAK/SYK inhibitor which is under investigation in a Phase IIb study for moderate-to-severe Atopic Dermatitis.

U.S. FDA Grants Fast Track Designation to Asana BioSciences’ Oral Dual JAK-SYK Inhibitor, ASN002, for the Treatment of Atopic Dermatitis

December 2018

LAWRENCEVILLE, N.J.--(BUSINESS WIRE, December 10, 2018) - Asana BioSciences, a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Asana’s investigational oral Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK) dual inhibitor ASN002 for the treatment of moderate-to-severe atopic dermatitis. 

CEOCFO Magazine Conducts Interview with Dr. Sandeep Gupta, Founder, President and CEO of Asana BioSciences

October 2018

CEOCFO Magazine, October 29, 2018 - CEOCFO Magazine has published an interview that was conducted with Dr. Sandeep Gupta, Founder, President and CEO of Asana BioSciences, which is developing an oral JAK/SYK inhibitor for moderate-to-severe Atopic Dermatitis and targeted therapies for advanced metastatic cancers.

Asana BioSciences to Present Late-Breaking Clinical and Biomarker Data for Its JAK/SYK Inhibitor ASN002 at the European Academy of Dermatology and Venereology (EADV) Annual Congress

September 2018

LAWRENCEVILLE, N.J., September 10, 2018 - Asana BioSciences, a clinical stage biopharmaceutical company, announced that it will present ASN002 data demonstrating improvements in skin pathology, disease related genes and inflammation biomarkers, correlating with clinical efficacy, in patients with moderate-to-severe atopic dermatitis. These data will be presented in the late breaking news session at the EADV Annual Congress in Paris, France, to be held September 12-16, 2018.

Asana BioSciences Initiates Phase 2b Study of ASN002 in Patients with Moderate-to-Severe Atopic Dermatitis (RADIANT)

July 2018

Lawrenceville, N.J., July 19, 2018 – Asana BioSciences, a clinical stage biopharmaceutical company focused on discovery and development of novel targeted investigational medicines in Immunology/ Inflammation and Oncology, today announced initiation of a Phase 2b study of ASN002, an oral JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis (AD).

Asana BioSciences to Present Positive Clinical Efficacy and Skin Biomarker Data in Atopic Dermatitis Patients Treated with Its Novel Oral JAK/SYK Inhibitor, ASN002, at the International Investigative Dermatology Meeting

May 2018

Lawrenceville, N.J., May 8, 2018 – Asana BioSciences, a clinical stage biopharmaceutical company focused on development of novel treatments for autoimmune diseases and cancers, today announced that it will present efficacy and biomarker data from the clinical proof of concept study with ASN002, an oral, once-daily dual JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis at the International Eczema Council (IEC) meeting to be held in Orlando on May 16, 2018; and at the International Investigative Dermatology (IID) meeting in Orlando, May 16-19, 2018.

Asana BioSciences Announces Presentations of ASN003 (BRAF/PI3K inhibitor) and ASN007 (ERK1/2 inhibitor) at the American Association for Cancer Research Annual Meeting

April 2018

Lawrenceville, N.J., April 10, 2018 – Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that it will present updates for two of its lead molecules in clinical development at the American Association for Cancer Research (AACR) Annual Meeting being held in Chicago, IL, April 14-18, 2018. Download the full release for presentation details.

Asana BioSciences to Present Clinical Proof of Concept Study Results in Atopic Dermatitis with ASN002, A Novel Oral JAK/SYK Inhibitor, in the Late-Breaking Session at the American Association of Dermatology Annual Meeting

January 2018

Lawrenceville, N.J., January 31, 2018 – Asana BioSciences, a clinical stage biopharmaceutical company, today announced that it will present the clinical proof of concept study results with ASN002, an oral, once-daily dual JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis in the late-breaking session at the annual meeting of the American Association of Dermatology in San Diego to be held February 16 - 20, 2018. Download the full release for presentation details.

Asana BioSciences Announces Achievement of Positive Results in the Clinical Proof of Concept Study in Atopic Dermatitis with ASN002, A Novel Oral JAK/SYK Inhibitor

January 2018

Lawrenceville, N.J., January 4, 2018 – Asana BioSciences, a clinical stage biopharmaceutical company, today announced that ASN002, its oral, once daily dual JAK/SYK inhibitor, has achieved clinical efficacy in a proof of concept study in patients with moderate to severe atopic dermatitis.  In a double blind, placebo controlled, dose-ranging, Phase 1b study conducted at multiple sites in the USA and Canada, ASN002 met the safety and efficacy endpoints after 4 weeks of treatment and was well tolerated.

Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor

January 2018


Princeton, N.J., January 3, 2018 – Asana BioSciences, an oncology-focused, clinical stage biopharmaceutical company, today announced that the US FDA has accepted the IND application for ASN007, a potent and selective ERK1/2 inhibitor.

Asana BioSciences to Present Updates on its Oncology Development Pipeline at the
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 

October 2017

 

Lawrenceville, N.J. October 24, 2017 – Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that it will present updates regarding three of its lead molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Philadelphia, PA, October 26-30, 2017.

 

Download the full release for more details. 

Asana BioSciences Initiates Phase 2 Evaluation of ASN002,
a Novel SYK/JAK Inhibitor, in NHL, CLL and MF
Updated Clinical Data to Be Presented at ASCO

May 2017

 

Lawrenceville, N.J. May 30, 2017 – Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that one of its lead molecules, ASN002, has completed the dose escalation phase in patients with Non-Hodgkin’s Lymphoma (NHL) and is now being investigated in the Phase 2 part of a multicenter trial in multiple hematological indications including NHL, Chronic Lymphocytic Leukemia (CLL), and Myelofibrosis (MF).

 

Download the full release for more details. 

Asana BioSciences Highlights Progress in its Oncology Portfolio with New Data at AACR 2017 on ASN002, ASN003 and ASN004

March 2017

 

Lawrenceville, N.J. March 27, 2017 – Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that it will be presenting preclinical data regarding three of its lead molecules at the American Association for Cancer Research (AACR) Annual Meeting being held in Washington, DC, April 1-5, 2017.

 

Download the full release for more details. 

Recent News

Asana BioSciences Announces Acceptance of the IND Application for its Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis 

March 2017

 

Lawrenceville, N.J. March 16, 2017 – Asana BioSciences, LLC, a clinical stage biopharmaceutical company, today announced that the FDA has accepted the IND application for ASN002, a novel dual SYK-JAK inhibitor, for Atopic Dermatitis.

 

Download the full release for more details. 

Asana BioSciences Announces Dosing of First Patient in Phase 1 Trial of ASN003

January 2017

 

Lawrenceville, N.J. January 4, 2017 – Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that the first patient has been dosed in a Phase 1 trial for ASN003, a novel and highly selective B-RAF/phosphoinositide 3-kinase (PI3K) inhibitor. Activation of these two major signaling pathways has been implicated in abnormal cell growth in various human cancers including melanoma, colorectal, breast and lung.

 

Download the full release for more details. 

Asana BioSciences Announces Acceptance of its Third IND Application in Oncology

October 2016

 

Lawrenceville, N.J. October 4, 2016 – Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that the FDA has accepted the IND application for ASN003, a selective RAF/PI3K inhibitor.

 

Download the full release for more details. 

Asana Biosciences Offices
Asana BioSciences Moves to New Offices

August 2016

 

Lawrenceville, New Jersey, August 15, 2016 – Asana BioSciences, LLC has moved from its previous space in Bridgewater to the Princeton Pike Corporate Center at 1009 Lenox Drive in Lawrenceville, New Jersey. The company's office phone numbers have not changed.  

Click on the buttons below to view the new location on a map or read the full press release.

Asana BioSciences to Provide First Presentation of Pre-clinical Data on its Novel ERK 1/2 Inhibitor Program

April 2016

 

Bridgewater, New Jersey, April 14, 2016 – Asana BioSciences, LLC announced today that it will present preclinical data regarding its product candidate, ASN007A, at the American Association for Cancer Research (AACR) Annual Meeting, being held in New Orleans, Louisiana, from April 16-20, 2016.

 

Download the full release for more details. 

Asana BioSciences to Provide Updates on ASN002 and ASN003 at TAT 2016

March 2016

 

Bridgewater, New Jersey, March 18, 2016 – Asana BioSciences, LLC today announced that Dr. Drew Rasco of South Texas Accelerated Research Therapeutics, San Antonio, Texas, will present an update on ASN002, which the company is developing for non-Hodgkin’s lymphoma, at the 14th International Congress on Targeted Anticancer Therapies being held on March 21-23, 2016 in Washington, D.C. Dr. Rasco is the principal investigator of the ongoing clinical trial of ASN002.

 

Download the full release for more details. 

Dr. Kapil Dhringa
Asana BioSciences Appoints Dr. Kapil Dhingra to its Oncology Scientific Advisory Board

January 2016

 

Bridgewater, New Jersey, January 4, 2016 – Asana BioSciences, LLC today announced that Kapil Dhingra, M.D., has been appointed to its oncology scientific advisory board (SAB). Dr. Dhingra is the former head of Roche Oncology Clinical Development and the founder of KAPital Consulting, LLC.

 

Download the full release for more details. 

Asana to Present First Clinical Data of ASN002, a Novel SYK/JAK Inhibitor

November 2015

 

Bridgewater, New Jersey, November 30, 2015 – Asana BioSciences, LLC today announced that preclinical and early clinical data from its ongoing Phase I/II trial of ASN002, the company’s potent oral inhibitor of spleen kinase (SYK) and the Janus kinase (JAK) family, will be presented at the 57th American Society of Hematology (ASH) annual meeting and exposition being held December 5 - 8 in Orlando, Florida.

 

Download the full release for more details. 

Asana BioSciences to Present Pre-clinical Data for a Novel Dual Inhibitor of B-Raf and PI3 Kinase Pathway

November 2015

 

Bridgewater, N.J. November 2, 2015 – Asana BioSciences, LLC today announced that it will present preclinical data regarding its product candidate ASN003 at the AACR-NCI-EORTC Internati­onal Conference on Molecular Targets and Cancer Therapeutics meeting, being held in Boston, Massachusetts, from November 5 - 9, 2015.

 

Download the full release for more details.

Asana BioSciences Announces Appointment of Louis Denis, M.D. as Chief Medical Officer

October 2015

 

Bridgewater, N.J. October 26, 2015 – Asana BioSciences, LLC today announced the appointment of Louis Denis, M.D., as its chief medical officer.

 

Dr Denis is a medical oncologist with more than 20 years of academic and industry experience in clinical cancer drug development. He will be responsible for the overall strategic direction and medical oversight of the clinical development of Asana’s novel product candidates.

 

Download the full release for more details.

Asana BioSciences to present pre-clinical data for a novel dual inhibitor of SYK and JAK family kinases and  a 5T4-targeted antibody drug conjugate at the AACR Annual Meeting

April 2015

 

Bridgewater, N.J. April 15, 2015 – Asana BioSciences, LLC today announced that it will be presenting preclinical data regarding two of its lead molecules at the American Association for Cancer Research (AACR) Annual Meeting being held in Philadelphia, April 18-22, 2015.

 

Download the full release for further details about the presentation times and molecules presented.

 

Asana BioSciences presents pre-clinical data for ASN004, an antibody drug conjugate for the treatment of cancer, at the 5th Annual World ADC Summit

October 2014

 

Bridgewater, NJ (USA) October 27, 2014 – Asana BioSciences, LLC (“Asana”, www.asanabio.com), an independent member of the Amneal Alliance of Companies, today announced its participation in the 5th Annual World ADC Summit in San Diego, CA.  Roger A. Smith, PhD, Vice-President at Asana BioSciences, presented preclinical data regarding the novel ADC ASN004 for the treatment of various cancers at the conference on October 27, 2014. Dr. Smith explained “ASN004 is a 5T4-oncofetal glycoprotein targeted antibody drug conjugate (ADC) developed in collaboration with Mersana Therapeutics, Inc. that selectively targets tumor cells and employs Fleximer® linker technology.  ASN004 shows potent, selective antiproliferative activity in tumor cell lines, and causes complete tumor regression leading to tumor-free survivors in mouse models of human breast, gastric and other cancers. This novel ADC is efficacious at very low doses, well-tolerated and has successfully completed pilot toxicology assessments.  ASN004 has the potential to be a very effective treatment for a wide range of cancers.

 

Asana BioSciences, LLC, an Amneal Alliance Company, acquires branded drug discovery platform from Endo International plc

June 2014

 

Bridgewater, NJ (USA) June 03, 2014 – Asana BioSciences, LLC (“Asana”, www.asanabio.com), an independent member of the Amneal Alliance of Companies, has acquired the early stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. Asana is a research and development company specializing in the discovery and development of new chemical and biological entities. The company’s portfolio consists of multiple compounds for oncology and pain indications that are ready to enter clinical trials. Asana is based in Bridgewater, NJ and led by Dr. Sandeep Gupta, Chief Executive Officer, who, until recently, was the Senior Vice President of Discovery and Early Development at Endo Pharmaceuticals.

© 2019 Asana BioSciences, LLC.  All rights reserved.

New Location (close).JPG